Is DRUG or DTIL more undervalued in 2026?

CirclFi compares Bright Minds Biosciences Inc. (DRUG) and Precision BioSciences, Inc. (DTIL) using 13 institutional-grade valuation models. DRUG has a Quality of Company score of 4.4/10 while DTIL scores 5.6/10.

Which is a better buy — DRUG or DTIL?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do DRUG and DTIL valuations compare?

DRUG at $89.49 and DTIL at $6.92 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

DRUG vs DTIL Valuation Comparison 2026 — Intrinsic Value Analysis

DRUG

Biotechnology

Bright Minds Biosciences Inc.

Quality

4.4

out of 10

Value Trap

SAFE

Price

$89.49

Last close

Models

8/13

Active

DTIL

Biotechnology

Precision BioSciences, Inc.

Quality

5.6

out of 10

Value Trap

SAFE

Price

$6.92

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	DRUG Fair Value	DRUG Upside	DTIL Fair Value	DTIL Upside
Bayesian DCF	Intrinsic	$24.06	-73.1%	$3.87	-44.1%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$1.42	-98.3%	$2.65	-61.7%
PWERM	Option-Based	$85.26	-4.7%	$8.85	+27.9%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for DRUG vs DTIL — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

DRUG vs DTIL — Which Stock Is More Undervalued?

DTIL scores higher with a 5.6/10 quality rating vs DRUG's 4.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Bright Minds Biosciences Inc. (DRUG) and Precision BioSciences, Inc. (DTIL) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

DRUG currently trades at $89.49 with a QOC of 4.4/10, while DTIL trades at $6.92 with a QOC of 5.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).